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Introduction
Stroke refers to any vascular injury that reduces brain 
blood flow in the brain area and leads to brain neurological 
impairment. About 80% of brain strokes have an ischemic 
origin due to the obstruction of the cerebrospinal fluid 
and the rest is hemorrhagic which occurs due to intra-
cerebral hemorrhage (ICH) or subarachnoid hemorrhage 
(1,2). Stroke is the most common neurological disorder 
in the world and the most important cause of disability 
in different countries. The mortality rate of acute stroke 
in the first month of incidence is about 10%, and the rest 
is accompanied by a neurological defect (3-5). Usually, 
50%-70% of patients return to their initial function, 
15%-30% are permanently incapacitated and 20% need 
hospital care for three months. Although stroke is a 
disease which affects the elderly more, but one third of 
the patients are under the age of 65 (6). Strokes impose a 
very high cost to the health system of countries. Studies 
on the prevalence of acute stroke in Iran show that it is 
similar to that of Arab neighborhoods, and it is less than 
that of advanced countries. In the past, stroke treatment 
included stabilization, care and restoration of patients, but 
today with a better understanding of the pathophysiology 
of nerve damage and the new drugs, the treatment of the 
disease includes controlling the blood pressure using 
anticoagulants and thrombolytic drugs as well as invasive 
interventions with catheters and surgery (7,8).
Many studies have been conducted on the efficiency of 
recombinant tissue plasminogen activator (rt-PA) and 
findings have revealed acceptable outcomes concerning 
the prescription of this drug between 3 and 4.5 hours after 
the onset of the symptoms (9).
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Abstract
Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has 
acceptable results in patients with stroke. This study aimed to evaluate the three months 
prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA). 
Methods: This cross-sectional prospective study was conducted on 30 patients with cerebral 
ischemic stroke with the National Institutes of Health Stroke Scale (NIHSS) >5. Data such 
as demographic information, signs and symptoms, medical history, risk factors, focused 
neurological examination, and the NIHSS were collected for all patients. Then, all patients 
received 0.9 mg/kg of rt-PA as intravenous bolus doses and intravenous infusion under close 
monitoring in the emergency department. All patients were checked for necessary outcomes 
and also disability at the admission time, 7 days later and after three months all patients were 
checked again. All collected data were analyzed by appropriate tests using SPSS version 22.
Results: Of all patients, 63.3% were males and 36.7% were females. The mean age of the 
patients was 62.37 ± 12.62 years with a range of 40-91 years. The mean of NIHSS was 12.46 
± 4.28 at admission time, in day seven it was 8.06 ± 3.72 and in month three after treatment 
it was 3.62 ± 2.31. There was a significant relationship between age, place of residence and 
NIHSS. Thirty percent of patients had NIHSS more than 15 at admission time and after 7 days 
this rate reached to 10% and three months later it declined to 6.7%. These differences were 
statistically significant.
Conclusion: Intravenous thrombolytic therapy is associated with  proper short term results in 
most patients with ischemic stroke. 
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However, the use of this drug requires the proper awareness 
of the society in identifying stroke symptoms, early 
referral of patients, the quality of life, speed of laboratory 
and imaging services, timely visits by neurologist, early 
treatment and observing certain clinical principles (10,11). 
Due to several preventive factors in the prescription 
of the drug, only a small percentage of patients could 
receive the rt-PA (12). In 1996, the US Food and Drug 
Administration (FDA) approved the use of rt-PA in the 
treatment of ischemic stroke (13). According to the last 
guideline of the United States Cardiovascular and Stroke 
in 2010, intravenous rt-PA administration is considered to 
be the most effective treatment intervention in stroke. The 
use of rt-PA due to reduced patients’ inability, reduced 
hospitalization time and long- term treatment have saved 
millions of dollars and consequently the use of rt-PA for 
the treatment of stroke has increased. Due to the lack 
of infrastructure, expensive drugs, complications from 
administration of rt-PA and its low golden time from 
the onset of symptoms to prescription, its use has been 
limited. So, Thrombolytic therapy, despite the increased 
risk of bleeding (4.6%), reduces morbidity and mortality 
in patients with acute ischemic stroke (14,15). The aim 
of this study was to evaluate the clinical course and the 
prognosis of patients with cerebral ischemic stroke treated 
with rt-PA and its effective factors during three months.
Methods
This cross-sectional prospective study was undertaken on 
30 patients with ischemic stroke and the National Institutes 
of Health Stroke Scale (NIHSS) > 5 who were hospitalized 
in the neurology department of Alawi hospital in Ardabil 
during 2016-2018. Stroke confirmation was performed by 
a neurologist based on clinical symptoms and imaging. 
The inclusion criteria encompassed the age more than 18, 
patients referred to the hospital less than 4.5 hours after the 
onset of symptoms and the indication of rt-PA injection. 
The exclusion criteria included ICH, subarachnoid and 
subdural hemorrhage, contra indication of rt-PA use and 
having cerebral venous sinus thrombosis. The single dose 
of 0.9 mg/kg of rTPA within 3 to 4.5 hours after the start of 
stroke was injected intravenously for all patients and they 
were asked to return three months later for a final check. 
We collected data by a checklist in two steps. First, at 
baseline data concerning the guidelines for indication 
and contraindication of rt-PA prescription were collected 
using form 1. Based on form 2, Modified Rankin Scale 
and NIHSS were completed for all patients. Data were 
also gathered 7 days later. By the same token, all clinical 
and imaging findings as well as other clinical examination 
findings were checked for all referred patients and 
entered in a checklist. Three months later, NIHSS was 
evaluated for all patients who referred to the hospital. 
In order to evaluate patients’ disability, doctors checked 
the movement of eyes, legs, visibility, arm movement, 
facial paresis, limb ataxia, ability to speak and sensory 
impairment, dysarthria, extinction and neglect.
The NIHSS has 11 questions with scores from 0 (the 
lowest) to 4 (the highest). The minimum obtained score 
for the questionnaire is 0 and the maximum is 44. 
Collected data were analyzed using descriptive statistics 
such as table and graph and also analytical statistics such 
as t-test to compare the mean of score between the two 
groups. Also, ANOVA test was used to compare the mean 
of score between three groups. All tests were conducted 
using SPSS version 22. P value less than 5% was considered 
significant. 
Results
Of all patients, 63.3% were males and the rest were females. 
There was no significant relationship between gender 
and NIHSS at the time of admission, on the seventh day 
and the third month. The average age of the patients was 
62.37 ± 12.62 years with a range of 40-91. Concerning the 
place of residence, 76.6% of the patients lived in urban (n 
= 23) and the rest of them lived in rural areas (n = 7). 
There was a significant relationship between age, place of 
residence and NIHSS (Table 1). The average NIHSS in the 
first day was 12.46 ± 4.28, at the seventh day it was 8.06 ± 
3.72 and three months after treatment it was 3.62 ± 2.31. 
This difference was statistically significant (Figure 1). 
Regarding the NIHSS score, 30% of patients had a score 
above 15 at the time of admission. This score decreased to 
10% on the seventh day and it declined to 6.7% in the third 
month. The difference was statistically significant (Figure 
2). The mean time of patients’ arrival until receiving rtPA 
Table 1. Relationship between NIHSS, age and place of residence
Characteristics 
NIHSS
First day 7 days later 3 months later
Age 69-40 (n=21) 12.31 ± 4.13 7.82 ± 3.44 3.12 ± 2.09
≥70 (n=9) 13.26 ± 4.71 9.69 ± 4.37 54.2 ± 1.4
P value 0.019 0.006 0.012
Place of residence Urban (n = 23) 12.28 ± 4.36 7.87 ± 3.41 3.35 ± 2.12
Rural (n = 7) 12.96 ± 4.22 8.34 ± 3.86 3.86 ± 2.66
P value 0.017 0.033 0.038
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was 56.82 ± 34.21 minutes and the average duration of 
hospitalization in the stroke unit was 4.16 ± 2.65 days 
and the average number of hospitalization was 8.56 ± 3.24 
days. These findings were statistically significant (Table 
2). Ten percent of patients had ICH and 2 patients died.
Discussion
In this study, 63.3% of patients were males and 36.7% were 
females, but there was no significant relationship between 
sex and NIHSS. Emberson et al in a study in 2014 showed 
that having high age and stroke severity can increase 
the likelihood of ICH in the first few days after Activase 
(alteplase) therapy (16). In the present study, there was a 
significant relationship between age and NIHSS at all three 
times. Also, this study showed that Activase (alteplase) in 
the first 4.5 hours after stroke can improve the disease 
and lead to good outcomes in patients. In the present 
study, NIHSS score above 15 was also found in 30% of 
patients at admission time and it reached to 6.7% in the 
third month. Pashapour et al in a study in 2011 showed 
that thrombolytic therapy in ischemic stroke patients had 
short and intermediate results and in patients with small 
bowel obstruction the severity of the disease was less and 
recovery was in a high level (17). In 2013, Hatamabadi 
et al. in a study found that 30% of patients who received 
rt-PA had significant improvement during three months 
in comparison to patients who received placebo. In the 
present study the average NIHSS of patients at the time 
of arrival was 12.46 and it reached to 3.62 during three 
months. Also, in the above study, ICH in the placebo 
group was 0.6% and in the rTPA group it was 6.4%. In 
addition, the motility rate was 21% in placebo group and 
17% in rTPA group (18). Besides, we observed a significant 
relationship between the average score of NIHSS on the 
first day, seventh day and the third month after follow 
up with the severity of neurological defect. Campbell et 
al in a study in 2015 showed that rt-PA recipients had 
good clinical symptoms and CT scan within the first 4.5 
hours (19). In this study the average time of arrival of the 
patient and receive rt-PA was 56.82 ± 34.21 minutes and 
the average duration of hospitalization in the stroke unit 
was 4.24 ± 2.65 days and the average number of admission 
days was 8.56 ± 3.48. These findings were statistically 
significant. According to the results of this study, 30% of 
patients had a NIHSS score higher than 15 at the time of 
admission which after the treatment on the seventh day it 
reached to 10% and after three months it reached to 6.7%. 
The results of the study conducted by Adams et al in 2007 
showed that 6.4% of patients who received rTPA and 0.6% 
of patients receiving placebo had ICH. Also, acceptable 
outcomes were correlated with the severity of deficiency 
and age so that patients with NIHSS <20 and age <75 had 
the best response to treatment (1). In the present study, 
there was a significant relationship between patients over 
70 years and NIHSS levels at all three times.
Conclusion
This study showed that receiving the drug as soon as 
possible reduces the severity of post-stroke inability and 
if it is administered three hours after stroke, its outcome 
could be very beneficial to the patient during the treatment 
process. In order to minimize the time of referral by the 
Table 2. Relationship between time of hospitalization by NIHSS
Variables 
NIHSS
First day 7 days later 3 months later
P value P value P value
Mean of time from admission to receive rt-PA (min) 56.82 ± 34.21 <0.001 <0.001 0.002
Mean of time hospitalized in ward of neurology (day) 4.16 ± 2.65 0.007 0.003 0.005
Mean of total hospitalized days 8.56 ± 3.24 0.014 0.011 0.017
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Figure 1. The changes of NIHSS rate during the study times.
Figure 2. The trend of NIHSS >15 during the study times.
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patient to the hospital and diagnose the disease, adequate 
facilities such as early diagnose, transferred and treated 
must be provided for all patients. It is suggested that 
extensive studies be conducted with a larger sample size 
in the future. 
Limitation
A great deal of studies have been done concerning the 
limitation and barriers of the delivery or prescription of 
rTPA for patients with acute ischemic stroke and related 
factors. So, programing for raising the knowledge of 
people about the symptoms of stroke and providing more 
facilities in all hospitals could be essential in future.
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